OTCMKTS:RHHBY - Roche Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $385.00
  • Forecasted Upside: 819.73 %
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$41.86
▲ +0.75 (1.82%)

This chart shows the closing price for RHHBY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Roche Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RHHBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RHHBY

Analyst Price Target is $385.00
▲ +819.73% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Roche in the last 3 months. The average price target is $385.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 819.73% upside from the last price of $41.86.

This chart shows the closing price for RHHBY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 12 investment analysts is to hold stock in Roche. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 2 sell ratings
11/30/2020
  • 1 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 3 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 3 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 2 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 2 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/19/2022Credit Suisse GroupLower Price TargetNeutral ➝ NeutralCHF 370 ➝ CHF 350
5/13/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
5/12/2022Morgan StanleyLower Price TargetEqual Weight ➝ Equal WeightCHF 395 ➝ CHF 370
5/11/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
4/19/2022UBS GroupDowngradeNeutral ➝ Sell
4/14/2022BarclaysBoost Price TargetCHF 415 ➝ CHF 450
3/11/2022JPMorgan Chase & Co.Lower Price TargetNeutral ➝ NeutralCHF 390 ➝ CHF 370
2/28/2022Stifel NicolausInitiated CoverageBuy
1/4/2022JPMorgan Chase & Co.Boost Price TargetCHF 360 ➝ CHF 390
12/22/2021CitigroupInitiated CoverageBuy
10/13/2021Morgan StanleyReiterated RatingEqual Weight
9/7/2021UBS GroupReiterated RatingNeutral
8/2/2021JPMorgan Chase & Co.Reiterated RatingNeutral
7/27/2021Societe GeneraleReiterated RatingHold
7/23/2021BarclaysSet Price TargetOverweight$46.42
7/21/2021CowenInitiated CoverageOutperform
7/19/2021UBS GroupReiterated RatingNeutral
7/14/2021Jefferies Financial GroupUpgradeHold ➝ Buy
7/8/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
6/14/2021Berenberg BankReiterated RatingHold
6/10/2021Morgan StanleyReiterated RatingEqual Weight
6/2/2021Societe GeneraleDowngradeBuy ➝ Hold
3/16/2021Jefferies Financial GroupDowngradeHold
2/25/2021Berenberg BankReiterated RatingHold
2/24/2021Morgan StanleyReiterated RatingEqual Weight
2/17/2021UBS GroupDowngradeBuy ➝ Neutral
2/10/2021JPMorgan Chase & Co.Reiterated RatingNeutral
2/4/2021Oddo BhfDowngradeReduce ➝ Underperform
1/22/2021BarclaysReiterated RatingOverweight
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
1/12/2021UBS GroupReiterated RatingBuy
1/8/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
1/4/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
11/27/2020UBS GroupReiterated RatingBuy
10/16/2020UBS GroupReiterated RatingBuy
9/29/2020Berenberg BankInitiated CoverageHold
9/28/2020Societe GeneraleReiterated RatingBuy
8/18/2020Morgan StanleyReiterated RatingOverweight
7/29/2020UBS GroupReiterated RatingBuy
7/29/2020Morgan StanleyReiterated RatingOverweight
7/13/2020Sanford C. BernsteinInitiated CoverageOutperform
7/3/2020AlphaValueUpgradeReduce
5/15/2020BarclaysReiterated RatingOverweight
5/13/2020Wolfe ResearchUpgradeMarket Perform ➝ Outperform
4/30/2020HSBCUpgradeReduce ➝ Hold
4/28/2020UBS GroupReiterated RatingBuy
4/28/2020Morgan StanleyReiterated RatingOverweight
4/23/2020JPMorgan Chase & Co.Reiterated RatingOverweight
3/10/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
2/18/2020CitigroupUpgradeNeutral ➝ Buy
1/23/2020CowenInitiated CoverageBuy$48.00
12/23/2019CowenReiterated RatingBuy$42.00
12/23/2019Royal Bank of CanadaReiterated RatingOutperform
7/26/2019UBS GroupUpgradeNeutral ➝ Buy
6/20/2019Liberum CapitalDowngradeBuy ➝ Hold
6/20/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
1/28/2019Credit Suisse GroupUpgradeUnderperform ➝ Neutral
1/28/2019ArgusInitiated CoverageBuy ➝ Buy
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy
11/26/2018CitigroupReiterated RatingHold
11/19/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy
10/23/2018Wolfe ResearchInitiated CoverageMarket Perform
9/10/2018Bank of AmericaDowngradeBuy ➝ Neutral
7/26/2018CowenReiterated RatingBuy$34.00
5/25/2018Credit Suisse GroupReiterated RatingNeutral ➝ Underperform
5/10/2018Sanford C. BernsteinDowngradeOutperform ➝ Market Perform
3/27/2018Morgan StanleyDowngradeEqual Weight ➝ Underweight
1/15/2018Societe GeneraleDowngradeHold ➝ Sell
12/29/2017JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight
12/7/2017Piper Jaffray CompaniesReiterated RatingBuy
10/24/2017Berenberg BankDowngradeBuy ➝ Hold
10/18/2017CitigroupDowngradeBuy ➝ Neutral
9/26/2017BNP ParibasDowngradeNeutral ➝ Underperform
9/19/2017CowenReiterated RatingBuy$38.00
8/14/2017CowenSet Price TargetBuy$38.00
7/26/2017Morgan StanleyReiterated RatingOverweight ➝ Equal Weight
7/10/2017CowenSet Price TargetBuy$38.00
7/7/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
7/6/2017UBS GroupDowngradeBuy ➝ Neutral
6/30/2017Societe GeneraleDowngradeBuy ➝ Hold
6/20/2017BNP ParibasReiterated RatingOutperform ➝ Neutral
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/26/2021
  • 10 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
11/25/2021
  • 8 very positive mentions
  • 12 positive mentions
  • 8 negative mentions
  • 5 very negative mentions
12/25/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/24/2022
  • 11 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
2/23/2022
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/25/2022
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
4/24/2022
  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
5/24/2022

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Negative

Roche logo
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, the company supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. It has collaboration with Gilead Sciences, Inc. for COVID-19; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company also has a collaboration with Bristol Myers Squibb to advance personalized healthcare through digital pathology solutions. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $41.86
Low: $41.56
High: $42.10

50 Day Range

MA: $47.42
Low: $39.54
High: $53.44

52 Week Range

Now: $41.86
Low: $39.32
High: $53.86

Volume

9,070,373 shs

Average Volume

1,945,817 shs

Market Capitalization

$285.90 billion

P/E Ratio

N/A

Dividend Yield

1.90%

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Roche?

The following Wall Street analysts have issued reports on Roche in the last twelve months: Barclays PLC, Berenberg Bank, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Societe Generale, Stifel Nicolaus, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for RHHBY.

What is the current price target for Roche?

0 Wall Street analysts have set twelve-month price targets for Roche in the last year. Their average twelve-month price target is $385.00, suggesting a possible upside of 819.7%.
View the latest price targets for RHHBY.

What is the current consensus analyst rating for Roche?

Roche currently has 1 sell rating, 7 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RHHBY, but not buy more shares or sell existing shares.
View the latest ratings for RHHBY.

How do I contact Roche's investor relations team?

Roche's physical mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company's listed phone number is (161) 688-1111 and its investor relations email address is [email protected] The official website for Roche is www.roche.com. Learn More about contacing Roche investor relations.